Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Support Oncol ; 7(6): 225-8, 2009.
Article in English | MEDLINE | ID: mdl-20380330

ABSTRACT

According to the prescribing information, pegfilgrastim should not be administered within 14 days prior to, or within 24 hours after, the administration of cytotoxic chemotherapy. However, few data exist to support this recommendation. A single-institution retrospective review was conducted of all patients with ovarian or primary peritoneal cancer who received prophylactic pegfilgrastim on the same day as myelosuppressive chemotherapy from May 2003 to June 2006. Forty-six patients were treated for the following malignancies: 35 (76%) epithelial ovarian, 6 (13%) primary peritoneal, and 5 (11.0%) ovarian germ cell or stromal cell carcinoma. All patients met the current guidelines of using colony-stimulating factors for prophylaxis against febrile neutropenia. A total of 269 cycles of chemotherapy were administered. All patients received pegfilgrastim within 1 hour of the completion of chemotherapy administration. Grade 1 or 2 neutropenia developed in 10 cycles (3.7%), and the mean absolute neutrophil count was 4926/uL (range, 1,293-24,300). No patients had febrile neutropenic episodes, hospitalizations, or antibiotic use secondary to neutropenia, nor did they have dose reductions or chemotherapy delays due to neutropenia. Administration of pegfilgrastim on the same day as myelosuppressive chemotherapy in patients with ovarian or primary peritoneal cancer may be determined to be a convenient, safe, and effective approach.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Endometrial Stromal Tumors/drug therapy , Granulocyte Colony-Stimulating Factor/administration & dosage , Neoplasms, Germ Cell and Embryonal/drug therapy , Ovarian Neoplasms/drug therapy , Peritoneal Neoplasms/drug therapy , Adult , Aged , Aged, 80 and over , Endometrial Stromal Tumors/pathology , Female , Filgrastim , Humans , Leukocyte Count , Middle Aged , Neoplasms, Germ Cell and Embryonal/pathology , Neutropenia/chemically induced , Neutropenia/prevention & control , Ovarian Neoplasms/pathology , Peritoneal Neoplasms/pathology , Polyethylene Glycols , Recombinant Proteins , Retrospective Studies , Survival Rate , Treatment Outcome , Young Adult
2.
Expert Opin Investig Drugs ; 15(11): 1319-36, 2006 Nov.
Article in English | MEDLINE | ID: mdl-17040194

ABSTRACT

The incidence of oesophageal candidiasis, candidaemia and disseminated candidiasis has increased dramatically. In addition to the amphotericin B formulations and fluconazole, the echinocandins anidulafungin, caspofungin and micafungin and the newer triazoles posaconazole and voriconazole are in the last stages of development and are becoming available for the management of candidiasis. This review presents these new agents and addresses their role in the treatment of candidiasis. All new antifungal agents exhibit potent activity against Candida spp. and echinocandins are fungicidal against most Candida spp. but appear to be less potent against certain species, such as Candida parapsilosis and C. guilliermondii. Systemic antifungal therapy can now be individualised based on the severity of the infection, comorbid conditions and the Candida spp. causing the infection. Studies are needed to investigate the possible development of resistance and the efficacy of these antifungal agents against the more resistant Candida spp.


Subject(s)
Antifungal Agents/therapeutic use , Candidiasis/drug therapy , Drugs, Investigational/therapeutic use , Animals , Candida/drug effects , Clinical Trials as Topic , Drug Evaluation, Preclinical , Humans , Microbial Sensitivity Tests
SELECTION OF CITATIONS
SEARCH DETAIL
...